Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases
Breast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local therapies (surgery, radiotherapy) and systemic treatments. Developing newer antibody–drug conjugates (ADCs) has...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-11-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359241292266 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846168769981841408 |
|---|---|
| author | Stacey Pan Jayant Y. Gadrey Sarah Sammons Nancy U. Lin Sara M. Tolaney Paolo Tarantino Ilana Schlam |
| author_facet | Stacey Pan Jayant Y. Gadrey Sarah Sammons Nancy U. Lin Sara M. Tolaney Paolo Tarantino Ilana Schlam |
| author_sort | Stacey Pan |
| collection | DOAJ |
| description | Breast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local therapies (surgery, radiotherapy) and systemic treatments. Developing newer antibody–drug conjugates (ADCs) has sparked a revolution in metastatic breast cancer (MBC) care. ADCs such as ado-trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan have demonstrated significant improvement in patient outcomes and are standard of care in the treatment of MBC. Most of the ADC registration studies included patients with stable BMs but excluded individuals with active BM, making intracranial (IC) response assessment a challenge. Promising data has recently emerged, suggesting relevant IC activity for certain ADCs and ongoing studies in patients with active BM that will expand our knowledge. This review aims to summarize the effectiveness of approved ADCs as well as promising new ADCs in development for breast cancer with BM. |
| format | Article |
| id | doaj-art-228052a30a8c47edb31a02d73a0d9afb |
| institution | Kabale University |
| issn | 1758-8359 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-228052a30a8c47edb31a02d73a0d9afb2024-11-13T12:03:20ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592024-11-011610.1177/17588359241292266Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastasesStacey PanJayant Y. GadreySarah SammonsNancy U. LinSara M. TolaneyPaolo TarantinoIlana SchlamBreast cancer remains a leading cause of brain metastases (BM), which carry a poor prognosis. The current approach to managing BMs in breast cancer patients involves a combination of local therapies (surgery, radiotherapy) and systemic treatments. Developing newer antibody–drug conjugates (ADCs) has sparked a revolution in metastatic breast cancer (MBC) care. ADCs such as ado-trastuzumab emtansine, trastuzumab deruxtecan, and sacituzumab govitecan have demonstrated significant improvement in patient outcomes and are standard of care in the treatment of MBC. Most of the ADC registration studies included patients with stable BMs but excluded individuals with active BM, making intracranial (IC) response assessment a challenge. Promising data has recently emerged, suggesting relevant IC activity for certain ADCs and ongoing studies in patients with active BM that will expand our knowledge. This review aims to summarize the effectiveness of approved ADCs as well as promising new ADCs in development for breast cancer with BM.https://doi.org/10.1177/17588359241292266 |
| spellingShingle | Stacey Pan Jayant Y. Gadrey Sarah Sammons Nancy U. Lin Sara M. Tolaney Paolo Tarantino Ilana Schlam Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases Therapeutic Advances in Medical Oncology |
| title | Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases |
| title_full | Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases |
| title_fullStr | Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases |
| title_full_unstemmed | Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases |
| title_short | Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases |
| title_sort | role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases |
| url | https://doi.org/10.1177/17588359241292266 |
| work_keys_str_mv | AT staceypan roleofantibodydrugconjugatesinthetreatmentofpatientswithbreastcancerbrainmetastases AT jayantygadrey roleofantibodydrugconjugatesinthetreatmentofpatientswithbreastcancerbrainmetastases AT sarahsammons roleofantibodydrugconjugatesinthetreatmentofpatientswithbreastcancerbrainmetastases AT nancyulin roleofantibodydrugconjugatesinthetreatmentofpatientswithbreastcancerbrainmetastases AT saramtolaney roleofantibodydrugconjugatesinthetreatmentofpatientswithbreastcancerbrainmetastases AT paolotarantino roleofantibodydrugconjugatesinthetreatmentofpatientswithbreastcancerbrainmetastases AT ilanaschlam roleofantibodydrugconjugatesinthetreatmentofpatientswithbreastcancerbrainmetastases |